Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jan 15;101(2):471–478. doi: 10.1172/JCI1113

Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies.

O E Brodde 1, U Konschak 1, K Becker 1, F Rüter 1, U Poller 1, J Jakubetz 1, J Radke 1, H R Zerkowski 1
PMCID: PMC508587  PMID: 9435320

Abstract

The M1 muscarinic receptor antagonist pirenzepine in low doses decreases resting heart rate; this effect declines with age (Poller, U., G. Nedelka, J. Radke, K. Pönicke, and O.-E. Brodde. 1997. J. Am. Coll. Cardiol. 29:187-193). To study possible mechanisms underlying this effect, we assessed (a) in six young (26 yr old) and six older volunteers (61 yr old), pirenzepine effects (0.32 and 0.64 mg intravenous [i.v.] bolus) on isoprenaline-induced heart rate increases; (b) in five heart transplant recipients, pirenzepine effects (0.05-10 mg i.v. bolus) on resting heart rate in the recipient's native and transplanted sinus nodes; and (c) in right atria from 39 patients of different ages (5 d-76 yr) undergoing open heart surgery, M2 muscarinic receptor density (by [3H]N-methyl-scopolamine binding) and adenylyl cyclase activity. (a) Pirenzepine at both doses decreased heart rate in young volunteers significantly more than in older volunteers; (b) pirenzepine (< 1 mg) decreased resting heart rate in the recipient's native but not transplanted sinus node; and (c) M2 receptor density and carbachol-induced inhibition of forskolin-stimulated adenylyl cyclase activity decreased significantly with the age of the patients. We conclude that pirenzepine decreases heart rate via inhibition of presynaptic M1 autoreceptors, thereby releasing endogenous acetylcholine, and that the heart rate-decreasing effect of acetylcholine declines with age because right atrial M2 receptor density and function decrease.

Full Text

The Full Text of this article is available as a PDF (286.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold J. M., McDevitt D. G. Vagal activity is increased during intravenous isoprenaline infusion in man. Br J Clin Pharmacol. 1984 Sep;18(3):311–316. doi: 10.1111/j.1365-2125.1984.tb02469.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bognar I. T., Beinhauer B., Kann P., Fuder H. Different muscarinic receptors mediate autoinhibition of acetylcholine release and vagally-induced vasoconstriction in the rat isolated perfused heart. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):279–287. doi: 10.1007/BF00180652. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Brehm G., Lindmar R., Löffelholz K. Inhibitory and excitatory muscarinic receptors modulating the release of acetylcholine from the postganglionic parasympathetic neuron of the chicken heart. Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):375–382. doi: 10.1007/BF00171077. [DOI] [PubMed] [Google Scholar]
  5. Bristow M. R. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):61A–71A. doi: 10.1016/0735-1097(93)90465-d. [DOI] [PubMed] [Google Scholar]
  6. Brodde O. E., Hillemann S., Kunde K., Vogelsang M., Zerkowski H. R. Receptor systems affecting force of contraction in the human heart and their alterations in chronic heart failure. J Heart Lung Transplant. 1992 Jul-Aug;11(4 Pt 2):S164–S174. [PubMed] [Google Scholar]
  7. Brodde O. E., Zerkowski H. R., Schranz D., Broede-Sitz A., Michel-Reher M., Schäfer-Beisenbusch E., Piotrowski J. A., Oelert H. Age-dependent changes in the beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium. J Cardiovasc Pharmacol. 1995 Jul;26(1):20–26. doi: 10.1097/00005344-199507000-00004. [DOI] [PubMed] [Google Scholar]
  8. Böhm M., Gierschik P., Jakobs K. H., Pieske B., Schnabel P., Ungerer M., Erdmann E. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990 Oct;82(4):1249–1265. doi: 10.1161/01.cir.82.4.1249. [DOI] [PubMed] [Google Scholar]
  9. Docherty J. R. Cardiovascular responses in ageing: a review. Pharmacol Rev. 1990 Jun;42(2):103–125. [PubMed] [Google Scholar]
  10. Eglen R. M., Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 1996 Feb;78(2):59–68. doi: 10.1111/j.1600-0773.1996.tb00181.x. [DOI] [PubMed] [Google Scholar]
  11. Epstein A. E., Hirschowitz B. I., Kirklin J. K., Kirk K. A., Kay G. N., Plumb V. J. Evidence for a central site of action to explain the negative chronotropic effect of atropine: studies on the human transplanted heart. J Am Coll Cardiol. 1990 Jun;15(7):1610–1617. doi: 10.1016/0735-1097(90)92834-o. [DOI] [PubMed] [Google Scholar]
  12. Feldman R. D. Physiological and molecular correlates of age-related changes in the human beta-adrenergic receptor system. Fed Proc. 1986 Jan;45(1):48–50. [PubMed] [Google Scholar]
  13. Fields J. Z., Roeske W. R., Morkin E., Yamamura H. I. Cardiac muscarinic cholinergic receptors. Biochemical identification and characterization. J Biol Chem. 1978 May 10;253(9):3251–3258. [PubMed] [Google Scholar]
  14. Folkow B., Svanborg A. Physiology of cardiovascular aging. Physiol Rev. 1993 Oct;73(4):725–764. doi: 10.1152/physrev.1993.73.4.725. [DOI] [PubMed] [Google Scholar]
  15. Giraldo E., Martos F., Gomez A., Garcia A., Vigano M. A., Ladinsky H., Sanchez de La Cuesta F. Characterization of muscarinic receptor subtypes in human tissues. Life Sci. 1988;43(19):1507–1515. doi: 10.1016/0024-3205(88)90398-0. [DOI] [PubMed] [Google Scholar]
  16. Habermeier-Muth A., Altes U., Forsyth K. M., Muscholl E. A presynaptic excitatory M1 muscarine receptor at postganglionic cardiac noradrenergic nerve fibres that is activated by endogenous acetylcholine. Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):483–489. doi: 10.1007/BF00169033. [DOI] [PubMed] [Google Scholar]
  17. Jeck D., Lindmar R., Löffelholz K., Wanke M. Subtypes of muscarinic receptor on cholinergic nerves and atrial cells of chicken and guinea-pig hearts. Br J Pharmacol. 1988 Feb;93(2):357–366. doi: 10.1111/j.1476-5381.1988.tb11442.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kent K. M., Epstein S. E., Cooper T., Jacobowitz D. M. Cholinergic innervation of the canine and human ventricular conducting system. Anatomic and electrophysiologic correlations. Circulation. 1974 Nov;50(5):948–955. doi: 10.1161/01.cir.50.5.948. [DOI] [PubMed] [Google Scholar]
  19. Koglin J., Böhm M., von Scheidt W., Stäblein A., Erdmann E. Antiadrenergic effect of carbachol but not of adenosine on contractility in the intact human ventricle in vivo. J Am Coll Cardiol. 1994 Mar 1;23(3):678–683. doi: 10.1016/0735-1097(94)90754-4. [DOI] [PubMed] [Google Scholar]
  20. Koglin J., Gross T., Uberfuhr P., von Scheidt W. Time-dependent decrease of presynaptic inotropic supersensitivity: physiological evidence of sympathetic reinnervation after heart transplantation. J Heart Lung Transplant. 1997 Jun;16(6):621–628. [PubMed] [Google Scholar]
  21. Lakatta E. G. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993 Apr;73(2):413–467. doi: 10.1152/physrev.1993.73.2.413. [DOI] [PubMed] [Google Scholar]
  22. Landzberg J. S., Parker J. D., Gauthier D. F., Colucci W. S. Effects of intracoronary acetylcholine and atropine on basal and dobutamine-stimulated left ventricular contractility. Circulation. 1994 Jan;89(1):164–168. doi: 10.1161/01.cir.89.1.164. [DOI] [PubMed] [Google Scholar]
  23. Levy M. N. Sympathetic-parasympathetic interactions in the heart. Circ Res. 1971 Nov;29(5):437–445. doi: 10.1161/01.res.29.5.437. [DOI] [PubMed] [Google Scholar]
  24. Löffelholz K., Pappano A. J. The parasympathetic neuroeffector junction of the heart. Pharmacol Rev. 1985 Mar;37(1):1–24. [PubMed] [Google Scholar]
  25. Newton G. E., Parker A. B., Landzberg J. S., Colucci W. S., Parker J. D. Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. J Clin Invest. 1996 Dec 15;98(12):2756–2763. doi: 10.1172/JCI119101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pfeifer M. A., Weinberg C. R., Cook D., Best J. D., Reenan A., Halter J. B. Differential changes of autonomic nervous system function with age in man. Am J Med. 1983 Aug;75(2):249–258. doi: 10.1016/0002-9343(83)91201-9. [DOI] [PubMed] [Google Scholar]
  27. Pitschner H. F., Schlepper M., Schulte B., Volz C., Palm D., Wellstein A. Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci. 1989 Dec;Suppl:92–96. [PubMed] [Google Scholar]
  28. Pitschner H. F., Wellstein A. Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy. Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):207–210. doi: 10.1007/BF00174872. [DOI] [PubMed] [Google Scholar]
  29. Poller U., Nedelka G., Radke J., Pönicke K., Brodde O. E. Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers. J Am Coll Cardiol. 1997 Jan;29(1):187–193. doi: 10.1016/s0735-1097(96)00437-8. [DOI] [PubMed] [Google Scholar]
  30. Poller U., Schäfers R. F., Schmuck S., Jakubetz J., Radke J., Daul A. E., Pönicke K., Brodde O. E. Influence of atropine on the cardiovascular effects of noradrenaline and tyramine in elder volunteers. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):100–106. doi: 10.1007/pl00005016. [DOI] [PubMed] [Google Scholar]
  31. Roth G. S. Hormone receptor changes during adulthood and senescence: significance for aging research. Fed Proc. 1979 Apr;38(5):1910–1914. [PubMed] [Google Scholar]
  32. Salomon Y., Londos C., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974 Apr;58(2):541–548. doi: 10.1016/0003-2697(74)90222-x. [DOI] [PubMed] [Google Scholar]
  33. Schäfers R. F., Adler S., Daul A., Zeitler G., Vogelsang M., Zerkowski H. R., Brodde O. E. Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1994 Apr;23(5):1224–1233. doi: 10.1016/0735-1097(94)90615-7. [DOI] [PubMed] [Google Scholar]
  34. Sorota S., Adam L. P., Pappano A. J. Comparison of muscarinic receptor properties in hatched chick heart atrium and ventricle. J Pharmacol Exp Ther. 1986 Mar;236(3):602–609. [PubMed] [Google Scholar]
  35. Von Scheidt W., Böhm M., Stäblein A., Autenrieth G., Erdmann E. Antiadrenergic effect of M-cholinoceptor stimulation on human ventricular contractility in vivo. Am J Physiol. 1992 Dec;263(6 Pt 2):H1927–H1931. doi: 10.1152/ajpheart.1992.263.6.H1927. [DOI] [PubMed] [Google Scholar]
  36. Wellstein A., Pitschner H. F. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1988 Jul;338(1):19–27. doi: 10.1007/BF00168807. [DOI] [PubMed] [Google Scholar]
  37. White M., Leenen F. H. Aging and cardiovascular responsiveness to beta-agonist in humans: role of changes in beta-receptor responses versus baroreflex activity. Clin Pharmacol Ther. 1994 Nov;56(5):543–553. doi: 10.1038/clpt.1994.176. [DOI] [PubMed] [Google Scholar]
  38. White M., Roden R., Minobe W., Khan M. F., Larrabee P., Wollmering M., Port J. D., Anderson F., Campbell D., Feldman A. M. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation. 1994 Sep;90(3):1225–1238. doi: 10.1161/01.cir.90.3.1225. [DOI] [PubMed] [Google Scholar]
  39. Wilson R. F., Christensen B. V., Olivari M. T., Simon A., White C. W., Laxson D. D. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation. 1991 Apr;83(4):1210–1220. doi: 10.1161/01.cir.83.4.1210. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES